Summary of Use during Lactation

No information is available on the clinical use of pemigatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during pemigatinib therapy and for 1 week after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Pemigatinib

CAS Registry Number

1513857-77-6

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors